Vonaprument
Vonaprument (ANX-007) is an intravitreally injected C1q antibody fragment (with a molecular weight of approximately 48 kDa) and a human monoclonal antibody. Vonaprument inhibits the activation of the classical complement cascade by specifically recognizing the globular head of C1q and blocking substrate binding. After intravitreal injection, Vonaprument distributes to the retina, choroid and optic nerve, and achieves complete C1q target binding in the aqueous humor and retinal tissues. Vonaprument can be used in research related to neurodegenerative eye diseases such as age-related macular degeneration and glaucoma.
For research use only. We do not sell to patients.
- CAS No.: 3050549-24-8
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
immunoglobulin Fab VH-G1(CH1-10h)_L-kappa
Human
|
C1q 136 pM (EC50, Human) |
C1q 147 pM (EC50, Human serum) |
C1q 179 pM (EC50, Cynomolgus Monkey serum) |
Vonaprument (ANX007/ANX-007) (8-3000 ng/mL) binds with similar high affinity to human and cynomolgus monkey C1q, with EC50 values of 136 pM, 147 pM, and 179 pM for purified human C1q, human serum C1q, and cynomolgus monkey serum C1q, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mixed gender (female-only in single-dose study; male and female in repeat-dose studies), 2-4 years old, 2.1-3.7 kg[1]
-
Dosage:1 mg/eye; 2.5 mg/eye; 5 mg/eye
-
Administration:i.v.t.; single bilateral dose, or two bilateral doses on days 1 and 29
-
Result:Measured vitreous free drug levels through 4 weeks following single doses of 1 or 5 mg/eye, with an approximate 3-day vitreous half-life.
Recorded vitreous Cmax values of 468,000 ng/mL (1 mg/eye) and 2,010,000 ng/mL (5 mg/eye), with AUClast values of 46,500,000 h*ng/mL (1 mg/eye) and 247,000,000 h*ng/mL (5 mg/eye).
Detected free drug in perfused retina and choroid 4 weeks post-last dose, and up to 2 weeks post-last dose in optic nerve following repeat doses of 5 mg/eye.
Achieved near complete inhibition of free-C1q levels in all sampled ocular fluids and tissues at 2 weeks post-last dose, with suppression maintained in retina, choroid, vitreous, and aqueous humor at 4 weeks post-last dose.
Demonstrated a strong correlation between aqueous humor free-C1q suppression and vitreous and retina free-C1q suppression, and a weaker but significant correlation with choroid free-C1q suppression.
No drug-related adverse changes were observed across all dose levels.
C1q
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Fab'-G1-kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 3050549-24-8
-
SMILES
[Vonaprument]
-
Synonyms
ANX-007
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Grover A, et al. Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates. Investigative ophthalmology & visual science. 2023 Feb 01;64(2):3. [Content Brief]
[2]. Sun Y, et al. Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma. Ophthalmol Sci. 2023 Feb 24;3(2):100290. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vonaprument Related Classifications
HY-P992142 Related Classifications
Powered by Bioz